GLAXOSMITHKLINE PLC Form 6-K April 17, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending 17 April 2018

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No x

GlaxoSmithKline plc (the 'Company')

GlaxoSmithKline plc (the 'Company')

Transaction notification

a) Name

- 1. Details of PDMR/person closely associated with them ('PCA')
  - Ms E Walmsley
- b) Position/status Chief Executive Officer
- c) Initial notification/ Initial notification
- 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
   b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of
   3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
   Ordinary shares of 25 pence

			Ordinary shares of 25 pence
			each ('Ordinary Shares')
a)	Description of the financial	instrument	ISIN: GB0009252882

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. Price(s) Volume(s)
	£14.296 248.648
	£14.296 248.630
c) Price(s) and volume(s)	£14.296 270.719
	£14.296 270.702
	£14.296 947.431

Aggregated volume Price

1,986.129 £14.296

e)	Date of the transaction	2018-04-12
Ð	Place of the transaction	London Stock Exchange
1)		(XLON)

1.	Details of PDMR/person closely associa	ted with then	n ('PCA')
a)	Name	Mr R G Cor	nnor
b)	Position/status	President, G	ilobal
0)	1 Ostrion/status	Manufactur	ing & Supply
c)	Initial notification/	Initial notifi	cation
0)	amendment		
2.	Details of the issuer, emission allowance	e market parti	cipant, auction
	platform, auctioneer or auction monitor		
	Name	GlaxoSmith	
b)	LEI		TVUYLO1D793
_	Details of the transaction(s): section to b	•	•••
3.	instrument; (ii) each type of transaction;		e; and (iv) each
	place where transaction(s) has been cond		6.0.5
		-	ares of 25 pence
a)	Description of the financial instrument		ary Shares')
		ISIN: GB00	09252882
		Acquisition	of Ondinomy
		-	of Ordinary
		Shares follo	nt of dividends
b)	Nature of the transaction		eholders on 12
0)	Nature of the transaction	April 2018	
		1	in the Company's
			nual Bonus Plan.
		Price(s)	Volume(s)
		£14.296	168.936
		æ111290	100.900
		£14.296	140.960
c)	Price(s) and volume(s)		1100900
- /		£14.296	140.944
		£14.296	200.719
d)	Aggregated information		

Aggregated volume Price

651.559 £14.296

e)	Date of the transaction	2018-04-12
Ð	Place of the transaction	London Stock Exchange
1)		(XLON)

<ul><li>a)</li><li>b)</li><li>c)</li><li>2.</li></ul>	Details of PDMR/person closely associa Name Position/status Initial notification/ amendment Details of the issuer, emission allowance platform, auctioneer or auction monitor	Mr L Debruyne President, Global Vaccines Initial notification e market participant, auction
a) b)	Name LEI	GlaxoSmithKline plc 5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to b instrument; (ii) each type of transaction; place where transaction(s) has been cond	(iii) each date; and (iv) each
a)	Description of the financial instrument	each ('Ordinary Shares') ISIN: GB0009252882
b)	Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. Price(s) Volume(s) £14.296 236.924
c)	Price(s) and volume(s)	£14.296 236.907
		£14.296 300.644
d)	Aggregated information Aggregated volume Price	774.475 £14.296
e) f)	Date of the transaction Place of the transaction	2018-04-12 London Stock Exchange (XLON)

<sup>1.</sup> Details of PDMR/person closely associated with them ('PCA') Mr S Dingemans

a) Name

<ul><li>b)</li><li>c)</li><li>2.</li></ul>	Position/status Initial notification/ amendment Details of the issuer, emission allowance platform, auctioneer or auction monitor	Chief Finano Initial notific market parti	cation
a) b) 3.	Name	e repeated fo (iii) each dat	TVUYLO1D793 r (i) each type of
a)	Description of the financial instrument	Ordinary sha each ('Ordin ISIN: GB00	•
b)	Nature of the transaction	paid to share April 2018 of Shares held	wing the nt of dividends eholders on 12
c)	Price(s) and volume(s)	£14.296 £14.296 £14.296 £14.296	328.341 245.940 245.940 670.469

Aggregated information	
d) Aggregated volume Price	1,819.049 £14.296
<ul><li>e) Date of the transaction</li><li>Place of the transaction</li><li>f)</li></ul>	2018-04-12 London Stock Exchange (XLON)

. Details of PDMR/person closely associated with them ('PCA')		
a) Name	Mr N Hirons	
b) Position/status	SVP, Global Ethics & Compliance	
c) Initial notification/ amendment	Initial notification	

	Edgar Filing	J: GLAXOSN	/ITHKLINE PLC -
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	_	_
	Name	GlaxoSmith	·
b)			TVUYLO1D793
2	Details of the transaction(s): section to b instrument; (ii) each type of transaction;		
5.	place where transaction(s) has been cond		e, and (IV) each
	place where transaction(s) has been cone		ares of 25 pence
- )		each ('Ordin	-
a)	Description of the financial instrument	ISIN: GB00	09252882
b)	Nature of the transaction	paid to share April 2018 of Shares held	wing the nt of dividends cholders on 12
		£14.296	121.408
c)	Price(s) and volume(s)	£14.296	89.098
		£14.296	89.082
		£14.296	105.267
1)	Aggregated information		
d)	A garageted volume Price	526.263	
	Aggregated volume Price	£14.296	
		214.270	
e)	Date of the transaction	2018-04-12	
f)	Place of the transaction	London Stor	ck Exchange
1)		(XLON)	
1	Datails of DDMD/normalization	tad with than	
	Details of PDMR/person closely associat Name	Mr L Miels	I(ICA)
		President, G	lobal
b)	Position/status	Pharmaceuti	
c)	Initial notification/	Initial notifi	cation
0)	amendment		
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market parti	cipant, auction

1 2	2.	platform,	auctioneer	or	auction	monitor	
-----	----	-----------	------------	----	---------	---------	--

a)	Name	GlaxoSmithKline plc
b)	LEI	5493000HZTVUYLO1D793

3.	Details of the transaction(s): section to be repeated for (i) each type of . instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	
Ordinary shares of 2: each ('Ordinary Share		

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan. Price(s) Volume(s)
c) Price(s) and volume(s)	£14.296 190.616
Aggregated information d)	n/a (single transaction)
<ul><li>Aggregated volume Price</li><li>e) Date of the transaction</li><li>Place of the transaction</li><li>f)</li></ul>	2018-04-12 London Stock Exchange (XLON)

1					
1.	····· · · · · · · · · · · · · · · · ·				
a)	Name	Mr B McNamara			
<b>L</b> )	Desition Istatus	CEO, GSK Consumer			
D)	Position/status	Healthcare			
	Initial notification/				
c)	amendment	Initial notification			
		1			
2.	Details of the issuer, emission allowance	e market participant, auction			
	platform, auctioneer or auction monitor				
a)	Name	GlaxoSmithKline plc			
b)	LEI	5493000HZTVUYLO1D793			
	Details of the transaction(s): section to b	e repeated for (i) each type of			
3					
5.	3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each				
	place where transaction(s) has been conc				
		American Depositary Shares			
		('ADSs')			
a)	Description of the financial instrument	ISIN: US37733W1053			
í	•				
		Acquisition of ADSs			
		Acquisition of ADSs			
		following the re-investment			

b) Nature of the transaction

following the re-investment of dividends paid to shareholders on 12 April 2018 on ADSs held in the Company's Deferred Annual Bonus Plan.

	Price(s) \$40.62	Volume(s) 102.618
c) Price(s) and volume(s)		
	\$40.62	100.616

d)	Aggregated information Aggregated volume Price	203.235 \$40.62
e) f)	Date of the transaction Place of the transaction	2018-04-12 New York Stock Exchange (XNYS)

1.	Details of PDMR/person closely associa	ted with ther	n ('PCA')
a)	Name	Mr D S Rec	
	Position/status	Chief Strate	egy Officer
c)	Initial notification/ amendment	Initial notifi	cation
2.	Details of the issuer, emission allowance	e market part	icipant, auction
2.	platform, auctioneer or auction monitor		
a)	Name	GlaxoSmith	Kline plc
b)	LEI	5493000HZ	TVUYLO1D793
	Details of the transaction(s): section to b	e repeated for	or (i) each type of
3.	instrument; (ii) each type of transaction;	-	
	place where transaction(s) has been cond		
			ares of 25 pence
,	<b>T</b>	•	ary Shares')
a)	Description of the financial instrument	ISIN: GB00	•
		Acquisition	of Ordinary
		Shares follo	•
			nt of dividends
b)	Nature of the transaction		eholders on 12
0)	Nature of the transaction	•	on Ordinary
		-	in the Company's
			nnual Bonus Plan.
		Price(s)	Volume(s)
		£14.296	154.513
		£14.296	154.513
c)	Price(s) and volume(s)	£14.296	112.131
,			
		£14.296	112.115
		£14.296	194.831

d)	Aggregated information Aggregated volume Price	728.103 £14.296
e) f)	Date of the transaction Place of the transaction	2018-04-12 London Stock Exchange (XLON)
<ul> <li>c)</li> <li>2.</li> <li>a)</li> <li>b)</li> <li>3.</li> </ul>	Details of PDMR/person closely associa Name Position/status Initial notification/ amendment Details of the issuer, emission allowance platform, auctioneer or auction monitor Name LEI Details of the transaction(s): section to b instrument; (ii) each type of transaction; place where transaction(s) has been conce	Ms C Thomas SVP, Human Resources Initial notification e market participant, auction GlaxoSmithKline plc 5493000HZTVUYLO1D793 be repeated for (i) each type of (iii) each date; and (iv) each

b) Nature of the transaction	Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 12 April 2018 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.
	Price(s) Volume(s)
	£14.296 226.048 £14.296 226.048
c) Price(s) and volume(s)	£14.296 168.773
	£14.296 168.773
	£14.296 211.772

## d) Aggregated information

Aggregated volume Price

1,001.414 £14.296

e)	Date of the transaction	2018-04-12
f)	Place of the transaction	London Stock Exchange
I)		(XLON)

1.	Details of PDMR/person	closely	associated	with	them	('PCA')
		J				()

1. a)	Name	Ms K Terrel	· /
b)	Position/status	Chief Digita Officer	al & Technology
c)	Initial notification/ amendment	Initial notifi	cation
2.	Details of the issuer, emission allowance platform, auctioneer or auction monitor	e market parti	icipant, auction
a) b)	Name LEI	GlaxoSmith 5493000HZ	Kline plc TVUYLO1D793
3.	Details of the transaction(s): section to b	e repeated fo	or (i) each type of
5.	place where transaction(s) has been cond	lucted	
a)	Description of the financial instrument	American D ('ADSs') ISIN: US37	Depositary Shares 733W1053
,	Nature of the transaction	of dividends shareholder 2018 on AD Company's Bonus Plan. Price(s)	ne re-investment s paid to s on 12 April OSs held in the Deferred Annual Volume(s)
c)	Price(s) and volume(s)	\$40.62	34.022
d)	Aggregated information Aggregated volume Price	n/a (single t	ransaction)
e) f)	Date of the transaction Place of the transaction	2018-04-12 New York S (XNYS)	Stock Exchange

1.	Details of PDMR/person closely associated with them ('PCA')		
a)	Name	Mr P C Thomson	
b)	Position/status	President, Global Affairs	
c)	Initial notification/	Initial notification	
C)	amendment	Initial notification	

$\mathbf{r}$	Details of the issuer,	emission allowance	market participant,	auction
--------------	------------------------	--------------------	---------------------	---------

- <sup>2.</sup> platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
   b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of
- 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

			Ordinary shares of 25 pence
a)	Description of the financial instrument	instrument	each ('Ordinary Shares')
		msuument	ISIN: GB0009252882

b) Nature of the transaction	Shares foll re-investm paid to sha April 2018 Shares hele	n of Ordinary owing the ent of dividends reholders on 12 on Ordinary d in the Company's annual Bonus Plan. Volume(s) 138.304
c) Price(s) and volume(s)	£14.296	106.250

d)	Aggregated information Aggregated volume Price	376.366 £14.296
e) f)	Date of the transaction Place of the transaction	2018-04-12 London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr D E Troy SVP & General Counsel b) Position/status Initial notification/ Initial notification c) amendment Details of the issuer, emission allowance market participant, auction 2. platform, auctioneer or auction monitor a) Name GlaxoSmithKline plc b) LEI 5493000HZTVUYLO1D793 Details of the transaction(s): section to be repeated for (i) each type of 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted a) Description of the financial instrument American Depositary Shares ('ADSs')

#### ISIN: US37733W1053

	Acquisitio	n of ADSs	
	following	the re-investment	
	of dividends paid to		
b) Nature of the transaction	shareholde	ers on 12 April	
	2018 on A	DSs held in the	
	Company's Deferred Annual		
	Bonus Pla	n.	
	Price(s)	Volume(s)	
	\$40.62	131.482	
	\$40.62	131.482	
c) Price(s) and volume(s)	\$40.62	108.898	
	\$40.62	108.881	
	\$40.62	116.999	

d)	Aggregated information		
	Aggregated volume Price	597.742 \$40.62	
e) f)	Date of the transaction Place of the transaction	2018-04-12 New York Stock Exchange (XNYS)	

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: April 17, 2018

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc